How Boehringer Ingelheim is buttressing its US business
カートのアイテムが多すぎます
カートに追加できませんでした。
ウィッシュリストに追加できませんでした。
ほしい物リストの削除に失敗しました。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
How Boehringer Ingelheim is buttressing its US business
-
ナレーター：
-
著者：
このコンテンツについて
With a new president of U.S. pharma at the helm—and two key FDA approvals now in the books—Boehringer Ingelheim is sharpening its focus on the lucrative American market.
In this week’s episode of “The Top Line,” we dive into Boehringer Ingelheim’s latest regulatory successes, two crucial launches, and the German company’s expanding commercialization push in the U.S.
Fierce Pharma’s Fraiser Kansteiner sits down with Brian Hilberdink—who joined Boehringer as president of U.S. human pharma in February—to discuss his game plan to further unlock the American market and capitalize on key BI green lights in idiopathic pulmonary fibrosis and lung cancer.
To learn more about the topics in this episode:
- Boehringer Ingelheim breaks into oncology with FDA approval for lung cancer med Hernexeos
- Boehringer Ingelheim breathes new life into lung fibrosis field with FDA approval for Jascayd
- 'Crossing fingers': Boehringer awaits key FDA decisions to spearhead 'maturing' pipeline
- Chutes & Ladders—Boehringer snatches up LEO exec for US pharma team
See omnystudio.com/listener for privacy information.